Trial Condition(s):
Chronic Bronchitis, Disease Exacerbation
VICTOR - Avelox® intravenous (i.v.) in Acute Exacerbations of Chronic Bronchitis (VICTOR)
Bayer Identifier:
14495
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
This study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. Patients documented must suffer from an acute exacerbation of chronic bronchitis and take at least one dose of Moxifloxacin injection.The primary objective is to obtain clinical effectiveness and safety data of Moxifloxacin injection in the treatment of acute exacerbations of chronic bronchitis in patients in whom Moxifloxacin was routinely prescribed. The secondary objective is to find out the possible correlation between the risk factors (sex, smoking, number of previous exacerbations, etc) and AECB, the different treatment effectiveness according to Anthonisen classification. This study will also collect the data of pathogens by sputum culture and the defervescence time of Moxifloxacin injection in treating Acute Exacerbations of Chronic Bronchitis (AECB).
Inclusion Criteria
- Patients at least 18 years of age with a diagnosis of AECB treated with Moxifloxacin injection with/without sequential tablet treatment
Exclusion Criteria
- Exclusion criteria must be read in conjunction with the local product information
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Investigative Site Many Locations, China | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
VICTOR - Avelox® i.v. in Acute Exacerbations of Chronic Bronchitis
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- clinical cure rate:clinical cure was defined as disappearance of acute signs and symptomsTimeframe: up to 21 days
Secondary Outcome
- Time to cure: time when symptoms are disappeared after Moxifloxacin treatmentTimeframe: up to 21 days
- Improvement time: time when patients feel improvemenTimeframe: up to 21 days
- Time of patients recover from feverTimeframe: up to 21 days
- Clinical efficacy rate of MoxifloxacinTimeframe: up to 21 days
Additional Information
Copyright © Bayer
Powered by
